Stock RX BIOSYENT INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioSyent Inc.

Equities

RX

CA0906901081

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-04-26 pm EDT 		5-day change 1st Jan Change
8.51 CAD 0.00% Intraday chart for BioSyent Inc. +0.12% -7.70%
Apr. 22 BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index CI
Apr. 01 BioSyent To Present At LD Micro New York Investor Conference MT

Business Summary

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.

Sales per Business

CAD in Million2022Weight2023Weight Delta
Pharmaceutical
96.9 %
27 96.5 % 31 96.9 % +13.61%
Insecticide
3.1 %
1 3.5 % 1 3.1 % -0.21%

Sales per region

CAD in Million2022Weight2023Weight Delta
Canada
95.9 %
27 96.7 % 30 95.9 % +12.16%
Middle East
3.3 %
1 2.4 % 1 3.3 % +53.27%
United States
0.8 %
0 0.8 % 0 0.8 % +7.49%

Managers

Managers TitleAgeSince
René C. Goehrum CEO
 Chief Executive Officer 64 95-12-31
Robert March DFI
 Director of Finance/CFO - 18-09-09
Navid Ashrafi CTO
 Chief Tech/Sci/R&D Officer - 14-04-30
Neelu Atwal HRO
 Human Resources Officer - 18-12-31
Joost van der Mark PRN
 Corporate Officer/Principal - 15-07-31
Kevin Wilson PRN
 Corporate Officer/Principal - 12-02-29

Members of the board

Members of the board TitleAgeSince
Sara Elford BRD
 Director/Board Member 53 18-01-07
René C. Goehrum CEO
 Chief Executive Officer 64 95-12-31
Peter Lockhard BRD
 Director/Board Member 60 02-05-31
Larry Andrews BRD
 Director/Board Member 71 18-01-07
Joseph Arcuri BRD
 Director/Board Member 58 18-05-28
Stephen Wilton BRD
 Director/Board Member 63 14-01-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 12,010,552 7,261,102 ( 60.46 %) 213,343 ( 1.776 %) 60.46 %

Shareholders

NameEquities%Valuation
René C. Goehrum
19.12 %
2,259,761 19.12 % 14 M $
Fax Investments, Inc.
18.15 %
2,146,100 18.15 % 14 M $
Peter Lockhard
5.771 %
682,196 5.771 % 4 M $
Kevin Wilson
0.5555 %
65,664 0.5555 % 421 235 $
Robert March
0.4759 %
56,254 0.4759 % 360 869 $
Joost van der Mark
0.4460 %
52,730 0.4460 % 338 263 $
Seyed Ahmad Ashrafi
0.4064 %
48,038 0.4064 % 308 164 $
Sharan Raghubir
0.3552 %
41,994 0.3552 % 269 392 $
Sara Elford
0.2344 %
27,715 0.2344 % 177 792 $
Neelu Atwal
0.1707 %
20,175 0.1707 % 129 423 $

Company contact information

BioSyent, Inc.

2476 Argentia Road Suite 402

L5N 6M1, Mississauga

+

http://www.biosyent.com
address BioSyent Inc.(RX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.51 CAD
Average target price
9 CAD
Spread / Average Target
+5.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BIOSYENT INC. Stock BioSyent Inc.
-7.70% 72.15M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RX Stock
  4. Company BioSyent Inc.